Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 4 to 5 amino acid residues in defined sequence
Reexamination Certificate
2006-07-11
2006-07-11
Andres, Janet L. (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
4 to 5 amino acid residues in defined sequence
C530S300000
Reexamination Certificate
active
07074893
ABSTRACT:
The present invention relates generally to therapeutic methods and compositions. More particularly, methods and compositions to counteract and reverse disease-causing signaling defects in diseases with underlying signal transduction aberrations, including but not limited to Alzheimer's Disease.
REFERENCES:
patent: 4552891 (1985-11-01), Ho et al.
patent: 4588394 (1986-05-01), Schulte et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5004697 (1991-04-01), Pardridge
patent: 5051448 (1991-09-01), Shashoua
patent: 5130129 (1992-07-01), Pardridge
patent: 5147855 (1992-09-01), Gozes et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5169862 (1992-12-01), Burke et al.
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5354844 (1994-10-01), Beug et al.
patent: 5393773 (1995-02-01), Craig et al.
patent: 5525727 (1996-06-01), Bodor
patent: 5539085 (1996-07-01), Bischoff et al.
patent: 5554639 (1996-09-01), Craig et al.
patent: 5559103 (1996-09-01), Gaeta et al.
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5601835 (1997-02-01), Sabel et al.
patent: 5618803 (1997-04-01), Bodor
patent: 5624894 (1997-04-01), Bodor
patent: 5643207 (1997-07-01), Rise
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5801161 (1998-09-01), Merkus
patent: 5864037 (1999-01-01), Chasin et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 5972883 (1999-10-01), Gozes et al.
patent: 6042579 (2000-03-01), Elsberry et al.
patent: 6117454 (2000-09-01), Kreuter et al.
patent: 6132764 (2000-10-01), Li et al.
patent: 6153193 (2000-11-01), Kabanov et al.
patent: 6153200 (2000-11-01), Carson et al.
patent: 6172277 (2001-01-01), Tate et al.
patent: 6179826 (2001-01-01), Aebischer et al.
patent: 6753314 (2004-06-01), Giot et al.
patent: WO 90/14835 (1990-12-01), None
patent: WO 97/34002 (1997-09-01), None
Chen et al. (Jun. 15, 1992) “Studies of cloned 37-kDa subunit of activator 1 (replication factor C) of HeLa cells”. Proc Natl Acad Sci USA 89(12): 5211-5.
Auger I et al., “HLA-DR4 and HLA-DR10 Motifs That Carry Susceptibility To Rheumatoid Arthritis Bind 70-kD Heat Shock Proteins,”Nature Med2:306-310 (1996).
Basu S. et al., “CD91 is a common receptor for heat shock proteins gp96, hsp70, and calreticulin,”Immunity14: 303-313 (2001).
Benvenisty and Reshef,“Direct introduction of genes into rats and expression of the genes”Proc. Nat. Acad. Sci. USA, 83:9551-55 (1986).
Bickel et al., “Pharmacologic effectsin vivoin brain b yvector-mediated peptide drug delivery, ”Proc. Natl. Acad. Sci. USA90:2618-2622 (1993).
Borisova et al., “Behavior of a Short preSI Epitope on the Surface of Hepatitis B Core Particles, ”Biol Chem380:315-324 (1999).
Colaco CB et al., “Deficient repair of O6-methylguanine in lympocytes from rheumatoid arthritis may be and acquired defect, ”Clin Exp Immunol72:15-19 (1988).
Corder EH et al., “Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families, ”Science261:921-923 (1993).
Corder EH et al., “Protective effect of apolipoprotein E type 2 allele for late on onset Alzheimer disease, ”Nat Genet7:180-184 (1994).
Curran M et al., “HLA-DR antigens associated with major genetic risk for late-onset Alzheimer's disease, ”NeuroReport8:1467-1469 (1997).
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice, ”Proc. Nat. Acad. Sci. USA, 81:7529-33 (1984).
Eldred et al., “Orally Active Non-Peptide Fibrinogen Receptor (Gpllb/llla) Antagonists: Identification of 4-[4-[4-(Aminoiminomethyl)phenyl]-1- piperazinyl]-1- piperidineacetic Acid as a Long-Acting, Broad-Spectrum Antithrombotic Agent, ”J. Med. Chem.37:3882 (1994).
Fisher et al., “(±)-cis-2-Methyl-spiro (1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1agonist attenuates cognitive dysfunctions in AF64-treated rats, ”Neurosci Lett102:325-331 (1989).
Forsythe and Westbrooke, “Slow Excitatory Postsynaptic Currents Mediated By N-Methyl-D-Asparate Receptors On Cultured Mouse Central Neurones, ”J Physiol(Lond) 396:515-533 (1988).
Galea E and Feinstein DL., “Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP, ”FASEB J13:2125-2137 (1999).
Greegersen PK et al., “The Share Epitope Hypothesis: An Approach to Understanding The Molecular Genetics of Susceptibility to Rheumatoid Arthritis, ”Atrhritis Rheum30:1205-1213 (1987).
Ku et al., “Potent Non-peptide Fibrinogen Receptor Antagonists Which Present An Alternative Pharmacohore, ”J. Med. Chem.38:9 (1995).
Levitzki A., “Targeting signal transduction for disease therapy, ”Curr Opin Cell Biol8:239-244 (1996).
Linden et al., “Characterization of Human ABAdenosine Receptors: Radiogland Binding, Western Blotting, and Coupling to Gqin Human Embryonic Kidney 293 Cells and HMC-1 Mast Cells, ”Molecular Pharmacology56:705-713 (1999).
Lipman and Pearson, “Rapid and Sensitive Protein Similarity Searches, ”Science227:1435-1441 (1985).
McCurdy D et al., “Delayed Repair of DNA Damage by Ionizing Radiation in Cells from Patients with Juvenile Systemic Lupus Erythematosus and Rheumatoid Arthritis, ”Radiat Res147:48-54 (1997).
Nepom GT et al., “HLA Genes Associated With Rheumatoid Arthritis: Identification of Susceptibility Alleles Using Specific Oligonucleotide Probes, ”Arthritis Rheum32:15-21 (1989).
Pearson and Lipman, “Improved tools for biological Sequence comparison, ”Proc. Natl. Acad. Sci.(USA) 85:2444-2448 (1988).
Pericak-Vance MA et al., “Linkage Studies in Familial Alzheimer Disease: Evidance for Chromosome 19 Linkage, ”Am J Hum Genet48:1034-1050 (1991).
Pumpens P and Grens E., “Hepatitis B core particles as a universal display model: a structure-function basis for development, ”FEBS Lett442:1-6 (1999).
Strittmatter WJ and Roses AD, “Apolipoprotein E and Alzheimer disease, ”Proc Natl Acad Sci USA92:4725-4727 (1995).
Wagner, et al., “Transferin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells, ”Proc. Natl. Acad. Sci.,88:4255-4259 (1991).
Weisgraber KH., “Apolipoprotein E distribution among human plasma lioproteins: role of the cysteine-arginine interchange at residue 112, ”J Lipid Res31:1503-1511 (1990).
Weyand CM et al., “The Influence of HLA-DRBI Genes on Disease Severity in Rheumatoid Arthritis, ”Ann Intern Med117:10 801-806 (1992).
Wolff et al., “Direct Gene Transfer Into Mouse Muscle in Vivo, ”Science, 247: 1456-68 (1990).
Walker et al., “Proteopathy: The next therapeutic frontier?,”Curr Opin Investig Drugs,3(5):782-787 (2002).
Fitjohn et al., “Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein, ”J. Neuroscience,21(13):4691-4698 (2001).
Chapman et al., “Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice,”Nature Neuroscience,2:271-276 (1999).
Schenk et al., “Potential treatment oppertunities for alzheimer's disease through inhibition of secretases and Aβ immunization, ”J. Mole. Neuroscience,17:259-267 (2001).
Perdriger et al., “Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis, ”J. Rheumatology,24(7):1272-1276 (1997).
Auger et al., “A function for the QKRAA amino acid motif: mediating binding of DnaJ to DnaK, ”J. Clin Invest,99(8):1818-1822 (1997).
Singal et al., “Genetics of rheumatoid arthritis (RA): two separate regions in the major histocompatibility compex contribute to suscepitibility to RA, ”Immunology Letters,69:301-306 (1999).
Vitolo et al.
Holoshitz Joseph
Ling Song
Andres Janet L.
Medlen & Carroll LLP
Regents of the University of Michigan
Standley Steven H.
LandOfFree
Methods and compositions for the treatment of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531727